Noropsikiyatri Arsivi-Archives of Neuropsychiatry最新文献

{"title":"A Case of Dose-Dependent Lamotrigine-Induced Priapism in a Patient with Bipolar Disorder.","authors":"Mustafa Akkuş","doi":"10.29399/npa.28970","DOIUrl":"10.29399/npa.28970","url":null,"abstract":"<p><strong>Introduction: </strong>Priapism is defined as a prolonged and persistent erection of the penis without sexual stimulation. Priapism can be caused either by organic factors or as a side effect of drugs. Mood stabilizer induced priapism has been reported less frequently compared to other psychotropic agents. This paper reports a case of lamotrigine induced priapism.</p><p><strong>Case: </strong>A 24-year-old patient had a diagnosis of bipolar disorder for 4 years. He had been treated with lamotrigine (200 mg/day), sertraline (25 mg/day) and risperidone (2 mg/day) for last year. He developed priapism one week after the lamotrigine dose was increased to 300 mg/day during a depressive episode. Priapism improved the day after the lamotrigine dose was reduced to 250 mg/day.</p><p><strong>Conclusion: </strong>Epilepsy patients with lamotrigine-induced sexual dysfunction or priapism have been reported previously. In this case, a patient diagnosed with bipolar disorder developed dose dependent lamotrigine-induced priapism. In clinical practice, the possible risk of priapism should be taken into consideration in patients using lamotrigine, especially during dose increases.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"26-27"},"PeriodicalIF":1.1,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroserpin, Tissue Plasminogen Activator, Brain-Derived Neurotrophic Factor and Interleukin-6 Serum Levels in Patients with Bipolar Disorder.","authors":"Hasan Ünver, Hasan Karadağ, Fevzi Nuri Aydın, Güven Özkaya, Gamze Erzin","doi":"10.29399/npa.28981","DOIUrl":"10.29399/npa.28981","url":null,"abstract":"<p><strong>Introduction: </strong>Numerous hypotheses have been proposed for the pathophysiology of bipolar disorder (BD). This study aimed to evaluate serum neuroserpin (NSP), tissue plasminogen activator (tPA), interleukin-6 (IL-6), brain-derived neurotrophic factor (BDNF), high-sensitivity C-reactive protein (hsCRP), and sedimentation levels in patients with BD, based on the inflammatory and fibrinolytic system hypothesis, to understand the etiopathogenesis of BD. The second aim of our study was to determine the risk of developing BD type 1 by examining the relationship between tPA and NSP in patients diagnosed with BD type 1.</p><p><strong>Methods: </strong>The study included 80 euthymic outpatients with BD type 1 and 80 healthy controls (HC). Individuals with a Hamilton Depression Rating Scale (HAM-D) score of less than 7 and a Young Mania Rating Scale (YMRS) score of less than 4 who did not show any symptoms of mania, depression, or hypomania for the last 6 months were included in the study. In both groups, serum levels of NSP, tPA, IL-6, BDNF, hsCRP, and sedimentation were measured.</p><p><strong>Results: </strong>Compared to the healthy control group, the NSP and tPA levels were lower in the BD group (p<0.001). We found no linear relationship when we analyzed the relationship between tPA and NSP by excluding other variables. (p: 0.027).</p><p><strong>Conclusion: </strong>These findings suggest that tPA and NSP may serve as potential biomarkers for the euthymic period of BD type 1. These biomarkers may provide guidance in understanding the pathophysiology of bipolar disorder.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"28-34"},"PeriodicalIF":1.1,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849322/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Clinical Associations of A-Waves in Routine Nerve Conduction Studies: A Retrospective Analysis.","authors":"Tuba Akıncı, Egemen Kaan Çakar, Bade Güleç, Nurten Uzun Adatepe, Ayşegül Gündüz","doi":"10.29399/npa.28944","DOIUrl":"10.29399/npa.28944","url":null,"abstract":"<p><strong>Introduction: </strong>A-waves are late responses following the motor response during motor nerve conduction studies (NCSs) observed in healthy people and patients with neurological disorders. The aim was to define the prevalence and clinical associations of A-waves in a cohort referred to the electrophysiology laboratory for routine NCSs.</p><p><strong>Methods: </strong>This is a retrospective study. We analyzed the medical and electrophysiological data of 456 patients admitted to our neurophysiology laboratory between January 2022 and December 2022, evaluated by a single examiner (A.G.), and had F-wave studies.</p><p><strong>Results: </strong>We included 1197 nerves from 404 patients in this cohort. The most common diagnosis was entrapment neuropathy, followed by polyneuropathy, radiculopathy, motor neuron disease, myopathy, and other diagnoses. Twenty-five patients had multiple conditions, and 185 patients had no abnormal NCSs. The A-waves were seen in 42.2% of individuals with otherwise normal NCSs. The A-waves were most commonly found in patients with polyneuropathies, followed by motor neuron disorders, radiculopathy, and myopathy. However, the majority of polyneuropathy patients had multiple A-waves. A-waves were detected in 78 of 185 normal NCSs; 7 % had multiple A-waves. Multiple and single A-waves were more commonly recorded in the tibial nerves. The A-waves were more frequently observed in older subjects.</p><p><strong>Conclusions: </strong>Other than multiple A-waves, A-waves were commonly seen in subjects with normal NCSs. As far as we know, this is the first study reporting the presence of A-waves in myopathy and neuromuscular junction disorders. Still, this finding should be interpreted cautiously given the limited clinical data available.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"16-21"},"PeriodicalIF":1.1,"publicationDate":"2025-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849299/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychometric Properties of the Turkish Version of the Screen for Cognitive Impairment in Psychiatry (SCIP-TR).","authors":"Şükrü Alperen Korkmaz, Fatmagül Eda Köksalan, Sevinç Sürücü, Murat İlhan Atagün","doi":"10.29399/npa.29072","DOIUrl":"10.29399/npa.29072","url":null,"abstract":"<p><strong>Introduction: </strong>Given the critical significance of cognitive functions in daily life and social interactions, the Screen for Cognitive Impairment in Psychiatry (SCIP) scale is particularly important in clinical practice. It can be administered quickly and offers alternative forms, avoiding issues with lengthy administration or a lack of parallel forms. This study examined the psychometric properties of the Turkish version of the SCIP scale (SCIP-TR), which enables rapid and practical assessment of cognitive impairment in psychiatric settings.</p><p><strong>Methods: </strong>This study involved 137 healthy students and hospital staff aged 18-45. Three alternative forms of the SCIP scale were adapted into Turkish using direct and reverse translation methods, and experts approved them to ensure content validity. Participants were administered one of the three alternative forms of the SCIP-TR and the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS), the Standardized Mini-Mental State Examination (SMMSE), and the Cognitive Failures Questionnaire (CFQ) scales. Test-retest reliability was evaluated using different forms of the SCIP-TR at 2-7 day intervals. The feasibility, reliability, and validity of the SCIP-TR forms were examined.</p><p><strong>Results: </strong>The analysis showed no significant differences between the three forms in total scores. Cronbach's alpha (0.715-0.750) and omega coefficients (0.709-0.784) demonstrated that the scale had acceptable internal consistency. Correlation coefficients confirmed the scale's test-retest reliability. The exploratory factor analysis unveiled a single-factor structure that accounted for 50.2% of the total variance. The moderate correlation of SCIP-TR with B-CATS, which measures similar cognitive domains, supports convergent validity.</p><p><strong>Conclusions: </strong>Findings demonstrate the validity and reliability of the Turkish version of the SCIP as a simple and practical tool for screening cognitive impairment in the general population. Its simplicity, brevity, and lack of need for a technological platform make it suitable for integration into clinical practice. Further research on SCIP-TR is needed in a more diverse demographic, including those with mental health disorders.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"90-100"},"PeriodicalIF":1.1,"publicationDate":"2025-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Seropositivity Developed Against Specific Antigens of <i>Helicobacter pylori</i> in Neurodegenerative Diseases.","authors":"Ruveyda Akcin, Melih Tutuncu, Nazan Karagoz Sakallı, Hulya Apaydın, Melda Bozluolçay, Gunay Can, Aysun Soysal, Serhat Sirekbasan, Harika Oyku Dinc, Suat Saribas, Bekir Kocazeybek","doi":"10.29399/npa.29038","DOIUrl":"10.29399/npa.29038","url":null,"abstract":"<p><strong>Introduction: </strong>It is suggested that Helicobacter pylori (Hp) can reach the brain via the oral-nasal-olfactory route, through Hp-infected monocytes in the disrupted blood-brain barrier (BBB), or through a rapid retrograde neural network leading to neurodegeneration from the gastrointestinal tract (GIS) and may lead to neurodegenerative diseases such as Alzheimer's (AD), Parkinson's (PD) and Multiple sclerosis (MS). In this study, we aimed to evaluate the possible immunopathogenesis relationship between Hp-specific antigens and neurodegenerative diseases by determining the frequency of seropositivity against different specific antigens of Hp in diseases such as AD, PD and MS.</p><p><strong>Methods: </strong>In our cross-sectional, retrospective case-control study, the immunoreactivity frequencies of Hp-specific and non-specific CagA (p120), VacA (p95), p75, FSH (p67), UreB (p66), HSP homolog (p57), flagellin (p54), p50, p41, p33, OMP (p30), UreA (p29), p26, OMP (p19), p17 antigens were determined by Western Blot method in 36 AD, 35 PD, 91 MS cases with Hp-IgG reactivity, and 55 controls without a neurodegenerative/demyelinating by ELISA method.</p><p><strong>Results: </strong>No significant difference was found between the immunoreactivity frequencies of Hp antigens between AD and control groups (p>0.05). In the multivariate logistic analysis performed for PD cases, age ≥ 50 and immunoreactivity frequency of p19 were found to be independent risk factors (OR: 36.752, p<0.05) (OR: 5.570, p<0.05). In MS cases, immunoreactivity frequency of p17 antigen was found to be a risk factor (OR: 2.646, p<0.05). In addition, the mean level of Hp-IgG reactivity was found to be negatively associated with MS development (indicating an inverse correlation) in the control group compared to the MS group (OR: 0.585, p < 0.05). Furthermore, logistic regression analysis in the total study group revealed that the immunoreactivity frequency of the p17 antigen was identified as a risk factor for MS (OR: 2.438, p<0.05).</p><p><strong>Conclusion: </strong>Our data on AD cases are insufficient. In PD cases, the significantly higher frequency of immunoreactivity to the Hp-p19 antigen in individuals aged ≥50 years (OR=5.570) is noteworthy. In the MS group, the significantly high detection of Hp p17 antigen and its presence as a risk factor (OR=2.646), and the significantly high detection of p26 antigen suggest the relationship between these antigens and the MS development process. However, it is a fact that new and many prospective cohort-based case-control studies are needed to reveal this more clearly.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"65-72"},"PeriodicalIF":1.1,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12849278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146087932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Olfactory Hallucinations Leading to Weight Loss in a Patient with Migraine.","authors":"Mehmet Sabri Erdöl, Emel Ur Özçelik, Betül Baykan","doi":"10.29399/npa.29161","DOIUrl":"10.29399/npa.29161","url":null,"abstract":"<p><strong>Introduction: </strong>Olfactory auras, in the form of hallucinations or phantosmia without an actual stimulus, have been very rarely reported in patients with migraine. This case report aims to raise awareness by presenting a patient whose condition was delayed in diagnosis, resulting in significant weight loss.</p><p><strong>Case: </strong>An 18-year-old female presented with complaints of a foul smell sensation that began a year ago, followed by headaches, loss of appetite, and weight loss. The patient experienced a sensation of rotting and burnt plastic odors lasting 2-12 hours, followed by severe, widespread throbbing headaches lasting 2-6 hours. Her past medical history was unremarkable, and her physical examination was within normal limits. Laboratory tests showed low vitamin D3 levels and low-positive nonspecific antinuclear antibody (ANA) titers. Electroencephalography (EEG) was normal, and brain magnetic resonance imaging (MRI) revealed a few millimetric nonspecific ischemic gliotic foci without other abnormalities. Otorhinolaryngology (ENT) and psychiatric evaluations were unremarkable. The patient's symptoms were largely controlled with lamotrigine treatment.</p><p><strong>Results: </strong>Due to the rarity of olfactory hallucinations in migraine attacks, patients may experience delays in obtaining an accurate diagnosis and management. Increasing clinical awareness of this rare presentation is therefore of paramount importance.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"282-284"},"PeriodicalIF":1.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Challenging The Diagnosis of Multiple Sclerosis: Histopathological Insights Gained Through Brain Biopsies.","authors":"Esra Taşkıran, Bilgin Öztürk, Naim Ata, Şuayip Birinci, Ahmed Serkan Emekli, Murat Kürtüncü","doi":"10.29399/npa.29156","DOIUrl":"10.29399/npa.29156","url":null,"abstract":"<p><strong>Introduction: </strong>While tissue sampling through brain biopsy is rarely required throughout the Multiple sclerosis (MS) disease course, it remains essential in cases with atypical clinical or radiological findings where other diagnostic methods are inconclusive. This study aims to present brain biopsy findings in patients diagnosed with MS.</p><p><strong>Methods: </strong>MS patients were screened from the national database. Brain MRI scans of all MS patients who underwent brain biopsy were reviewed to confirm the compliance of MAGNIMS criteria. Data on MS diagnosis, biopsy date, disease-modifying therapy (DMT) use, and the duration of DMT exposure prior to biopsy were also collected. Pathology reports of brain biopsies were reviewed with these parameters.</p><p><strong>Results: </strong>Among 87,640 MS patients, 21 patients had brain biopsies after MS diagnosis, highlighting the rarity (0.02%) of this invasive procedure, with a median age at biopsy of 43 (IQR: 13) years. Pathological findings revealed 12 malignant diagnoses, including lymphoma, glioblastoma, metastasis, and nine non-malignant conditions, such as vasculitis, demyelination, and benign masses.</p><p><strong>Conclusion: </strong>Brain biopsy is rarely required in patients with MS; however, it should be considered in cases of atypical lesion development, underscoring the need for meticulous clinical monitoring.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"277-281"},"PeriodicalIF":1.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951494/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Large Artery Atherosclerosis and Predictive Risk Factors in Symptomatic and Asymptomatic Ischemic Stroke.","authors":"Eda Çoban, Elif Korkut, Fazilet Karademir, Rabia Karabıyık, Nilüfer Kale İçen","doi":"10.29399/npa.29224","DOIUrl":"10.29399/npa.29224","url":null,"abstract":"<p><strong>Introduction: </strong>Large-artery atherosclerosis (LAA) is common in acute ischemic stroke, before determinants of whether LAA presents symptomatically or remains silent are unclear. We aimed to identify risk factors distinguishing symptomatic from asymptomatic LAA.</p><p><strong>Methods: </strong>We retrospectively analyzed 411 consecutive patients (January 2020-January 2025) with acute ischemic stroke and imaging-confirmed ≥ 50% stenosis/occlusion. Demographics, comorbidities; Hypertension (HT), Diabetes mellitus (DM), Hyperlipidemia (HL), Atrial fibrillation (AF), and fasting laboratories were recorded; triglyceride-to-high-density lipoprotein (TG/HDL) and triglyceride-to-glucose (TG/Gl) indices were calculated. Vascular territory was classified (carotid, vertebrobasilar (VBS), carotid-vertebrobasilar system) via Doppler, brain computerised tomography (CT), and/or magnetic resonance imaging (MRI) angiography. Patients with ≥ 50% stenosis or occlusion in extra or intracranial arteries were classified as having LAA. Those with neurological deficits attributable to LAA were considered symptomatic, while patients with unrelated stroke etiologies were classified as asymptomatic. Group comparisons used chi-square, Mann-Whitney U, and Kruskal-Wallis tests.</p><p><strong>Results: </strong>The mean age was 70.4 ± 10.6 years; 38.2% were women. Territory involvement was 49.6% carotid, 21.2% vertebrobasilar, and 29.2% carotid-vertebrobasilar system. In younger patients (40-60 years), AF was associated with VBS involvement (p = 0.035). In the oldest group (81-99 years), HL was associated with VBS/carotid-VBS atherosclerosis (p = 0.003). Overall, 285 patients were symptomatic and 126 were asymptomatic. Hyperlipidemia was associated with symptomatic LAA (OR = 1.64; p = 0.023), remaining significant in men. AF was more frequent among asymptomatic LAA in those aged 61-99, suggesting cardioembolism predominated the index event while LAA remained silent. TG/HDL was higher in symptomatic women and elevated across symptomatic patients aged 40-80 (p = 0.010; borderline at 61-80 ages, p = 0.050). TG/Gl did not discriminate symptom status in any subgroup.</p><p><strong>Conclusion: </strong>In elderly patients, hypertension; in men, hyperlipidemia; and in women and middle-to-older age groups, elevated TG/HDL are linked to symptomatic conversion of LAA. In the presence of AF, concomitant LAA often remains clinically silent. Tight control of modifiable risks, may delay or prevent symptomatic transition of LAA and is an alternative for patients ineligible for intervention.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"316-320"},"PeriodicalIF":1.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship Between Neurofilament Light Chain and B Lymphocyte Chemoattractant and Cognition in Multiple Sclerosis.","authors":"Ezgi Bakırcıoglu-Duman, Fatma Belgin Petek-Balcı, Nurcihan Calıskan-Dolu, Ayse Ozlem Cokar","doi":"10.29399/npa.29126","DOIUrl":"10.29399/npa.29126","url":null,"abstract":"<p><strong>Introduction: </strong>Multiple sclerosis (MS) is a chronic inflammatory, autoimmune, demyelinating disease of the central nervous system that is often associated with cognitive impairment. This study aims to investigate whether Neurofilament light chain (NfL) and B Lymphocyte Chemoattractant (CXCL13) are potential biomarkers for detecting cognitive impairment in MS.</p><p><strong>Methods: </strong>57 patients with Radiologically Isolated Syndrome (RIS), Clinically Isolated Syndrome (CIS) or Relapsing-remitting MS (RRMS) and 70 healthy controls were studied. NfL and CXCL13 were measured by ELISA (the Enzyme-Linked ImmunoSorbent Assay) in the patients' cerebrospinal fluid (CSF) and serum samples. The Turkish-validated version of Brief International Cognitive Assessment for MS (BICAMS) test was applied. Serum biomarker levels and cognition tests were compared between the control and patient groups.</p><p><strong>Results: </strong>Serum NfL and CXCL13 values were significantly higher in the patient group (p = 0.043 and p < 0.001, respectively) compared to healthy controls. BICAMS were lower in the patient group (p<0.001). CSF CXCL13 levels demonstrated a significant negative correlation (p = 0.034) with California Verbal Learning Test-2 (CVLT-II) subtest scores, while CSF NfL levels showed a trend towards a negative association (p=0.067) with this subtest. There were no significant relationships between the serum or CSF biomarkers and the BICAMS total scores.</p><p><strong>Conclusion: </strong>NfL and CXCL13 potential biomarkers may not be associated with cognitive impairment in MS patients. The limitations of this study include the absence of CSF data from healthy individuals and the lack of stratification by clinical MS subtypes (RIS, CIS, or RRMS). Since they have been seen as promising biomarkers in MS, further studies are needed to determine this potential relationship.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"63 ","pages":"253-257"},"PeriodicalIF":1.0,"publicationDate":"2025-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12951504/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychiatric Presentation of Hereditary Coproporphyria with Coproporphyrinogen Oxidase Gene Mutation c.734 C>T: A Case Report.","authors":"Mert Şenel, Işık Batuhan Çakmak, Şahin Gürkan, Şükrü Alperen Korkmaz, Bengisu Çatlı, Ahmet Cevdet Ceylan, Gülten Burcu Civelek Ürey, Çiğdem Seher Kasapkara, Erol Göka","doi":"10.29399/npa.28917","DOIUrl":"10.29399/npa.28917","url":null,"abstract":"<p><strong>Introduction: </strong>Porphyrias constitute a collection of hereditary metabolic disorders arising from disturbances in the enzymatic activities inherent to the heme biosynthetic pathway. Eight subtypes of porphyria, each associated with enzymes in the heme biosynthesis pathway, have been identified. Hereditary coproporphyria is one of the porphyria subtypes characterized by neuropsychiatric clinical features. It develops as a result of a deficiency in coproporphyrinogen oxidase enzyme activity. Consequently, an accumulation of coproporphyrin and its precursor metabolites is observed. Hereditary coproporphyria exhibits autosomal dominant inheritance. Following clinical suspicion, a diagnosis is made with biochemical and genetic tests. The presence of nonspecific symptoms and the lack of consideration for porphyria in differential diagnosis complicate the diagnosis.</p><p><strong>Case: </strong>An 18-year-old male patient was referred to our psychiatry clinic only with psychiatric complaints. The mental status examination revealed affective signs, along with visual hallucinations and delusions. Blood tests and cranial scans at admission showed no abnormalities. After initiating treatment with valproic acid and olanzapine for a presumptive diagnosis of bipolar I disorder, a manic episode with psychotic features, the patient's general medical condition worsened. During clinical observation, the appearance of neurological and gastrointestinal system findings led to a reconsideration of the diagnosis, and porphyria was considered. Urine tests revealed elevated levels of porphyrin intermediates. The diagnosis of hereditary coproporphyria was confirmed by genetic testing, which identified the c.734 C>T mutation in the coproporphyrinogen oxidase gene. Symptomatic relief was observed following a carbohydrate-rich diet without the need for psychotropic treatment.</p><p><strong>Conclusion: </strong>Although their subtypes exhibit distinct clinical features, porphyrias typically present with involvement of multiple systems. Cases that initially present with symptoms specific to a single system can pose diagnostic challenges. In our case report, we aimed to present the psychiatric onset of hereditary coproporphyria, a rare subtype of porphyria known for its potentially fatal attacks when untreated.</p>","PeriodicalId":51142,"journal":{"name":"Noropsikiyatri Arsivi-Archives of Neuropsychiatry","volume":"62 4","pages":"390-392"},"PeriodicalIF":1.1,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12694772/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145745548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}